Suppliers for CAS
1270138-40-3
|
Properties | CAS |
1270138-40-3 | Formula |
C22H30N4O |
|
12 Registered suppliers
Sancai Industry Co.,Ltd.
P.R.China
Xingrui Industry Co., Limited
P.R.China
Leap Chem Co., Ltd
P.R.China
Molecular Formula: C22H30N4O Molecular Weight: 366.4998
Molecular Formula: C22H33N4O5P Molecular Weight: 464.494981
Wuhan PharmChem Co., LTD.
P.R.China
Molecular formula :C22H30N4O
Shandong Ench Chemical Co.,Ltd
P.R.China
Molecular formula :C22H30N4O
Aea.ltd
P.R.China
Molecular formula :C22H30N4O
Zehao Industry Co., Ltd.
P.R.China
Molecular formula :C22H30N4O
BOC Sciences
USA
Description : NSI-189 is an experimental drug being studied by Neuralstem, Inc. Research into NSI-189 has been funded by the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH) for the treatment of major depressive disorder. NSI-189 successfully completed a phase 1 clinical trial in 2011 where it was administered to 41 healthy volunteers. A phase 1b clinical trial for treating major depressive disorder in 24 patients started in 2012 and completed in July 2014. The study suggests that there were improvements in the patients' condition when the doses were 40/80 mg per day, but no significant improvements were seen for a higher dosage of 120 mg/day. Neuralstem intends to pursue further clinical trials for a variety of neurological conditions, including major depressive disorder, traumatic brain injury, Alzheimer's disease, post-traumatic stress disorder, stroke, and natural cognitive and memory decline in aging. - Molecular Weight :366.5
- Purity :98%
Molecular Formula : C22H30N4O Canonical SMILES : CC(C)CCNC1=C(C=CC=N1)C(=O)N2CCN(CC2)CC3=CC=CC=C3 InChI : InChI=1S/C22H30N4O/c1-18(2)10-12-24-21-20(9-6-11-23-21)22(27)26-15-13-25(14-16-26)17-19-7-4-3-5-8-19/h3-9,11,18H,10,12-17H2,1-2H3,(H,23,24) InChIKey : DYTOQURYRYYNOR-UHFFFAOYSA-N Appearance : Off-white powder Application : For research used only Synonyms : NSI-189; NSI 189; NSI189
More details are to be found here
Shandong SanYoung Industry Co., Ltd
P.R.China
Description : NSI-189 is an experimental drug being studied by Neuralstem, Inc. Research into NSI-189 has been funded by the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH) for the treatment of major depressive disorder. NSI-189 successfully completed a phase 1 clinical trial in 2011 where it was administered to 41 healthy volunteers. A phase 1b clinical trial for treating major depressive disorder in 24 patients started in 2012 and completed in July 2014. The study suggests that there were improvements in the patients' condition when the doses were 40/80 mg per day, but no significant improvements were seen for a higher dosage of 120 mg/day. Neuralstem intends to pursue further clinical trials for a variety of neurological conditions, including major depressive disorder, traumatic brain injury, Alzheimer's disease, post-traumatic stress disorder, stroke, and natural cognitive and memory decline in aging. - Molecular Weight :366.5
- Purity :98%
Molecular Formula : C22H30N4O Canonical SMILES : CC(C)CCNC1=C(C=CC=N1)C(=O)N2CCN(CC2)CC3=CC=CC=C3 InChI : InChI=1S/C22H30N4O/c1-18(2)10-12-24-21-20(9-6-11-23-21)22(27)26-15-13-25(14-16-26)17-19-7-4-3-5-8-19/h3-9,11,18H,10,12-17H2,1-2H3,(H,23,24) InChIKey : DYTOQURYRYYNOR-UHFFFAOYSA-N Appearance : Off-white powder Application : For research used only Synonyms : NSI-189; NSI 189; NSI189
More details are to be found here
Autech Industry Co.,Limited
P.R.China
Description : NSI-189 is an experimental drug being studied by Neuralstem, Inc. Research into NSI-189 has been funded by the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH) for the treatment of major depressive disorder. NSI-189 successfully completed a phase 1 clinical trial in 2011 where it was administered to 41 healthy volunteers. A phase 1b clinical trial for treating major depressive disorder in 24 patients started in 2012 and completed in July 2014. The study suggests that there were improvements in the patients' condition when the doses were 40/80 mg per day, but no significant improvements were seen for a higher dosage of 120 mg/day. Neuralstem intends to pursue further clinical trials for a variety of neurological conditions, including major depressive disorder, traumatic brain injury, Alzheimer's disease, post-traumatic stress disorder, stroke, and natural cognitive and memory decline in aging. - Molecular Weight :366.5
- Purity :98%
Molecular Formula : C22H30N4O Canonical SMILES : CC(C)CCNC1=C(C=CC=N1)C(=O)N2CCN(CC2)CC3=CC=CC=C3 InChI : InChI=1S/C22H30N4O/c1-18(2)10-12-24-21-20(9-6-11-23-21)22(27)26-15-13-25(14-16-26)17-19-7-4-3-5-8-19/h3-9,11,18H,10,12-17H2,1-2H3,(H,23,24) InChIKey : DYTOQURYRYYNOR-UHFFFAOYSA-N Appearance : Off-white powder Application : For research used only Synonyms : NSI-189; NSI 189; NSI189
More details are to be found here
Chemlyte Solutions
P.R.China
More details are to be found here
World. Chem. Co., Ltd.
P.R.China
Appearance | white Powder
| Purity | 99% |
Detailed information on the suppliers of
NSI-189
|